Weighing In On DPP-IV Inhibitors: Galvus, Januvia Both Highlight Weight Profiles

Data presented on the competing dipeptidyl peptidase IV inhibitors from Novartis and Merck at the American Diabetes Association similarly tout weight loss and other side effect advantages versus standard type 2 diabetes drugs.